REC Share Price | Recordati SpA Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

767.66 k

Shareholding (Dec 2025)

FII

0.01%

Held by 3 FIIs

DII

99.99%

Held by 0 DIIs

Promoter

0.00%

Compare Recordati SpA with Similar Stocks

Philogen SpA Fine Foods & Pharmaceuticals N.T.M. SpA Friulchem SpA

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Operating profit has grown by an annual rate 6.94% of over the last 5 years

With ROE of 23.07%, it has a Very Expensive valuation with a 5.79 Price to Book Value

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

EUR 10,000 Million ()

P/E

25.00

Industry P/E

Dividend Yield

22.65%

Debt Equity

0.86

Return on Equity

22.64%

Price to Book

5.19

Revenue and Profits:

Net Sales:

662 Million

(Quarterly Results - Dec 2025)

Net Profit:

117 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-12.4%

6 Months

19.16%

1 Year

40.86%

2 Years

30.8%

3 Years

16.38%

4 Years

54.2%

5 Years

90.19%

Recordati SpA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.61%

EBIT Growth (5y)

6.94%

EBIT to Interest (avg)

16.62

Debt to EBITDA (avg)

1.95

Net Debt to Equity (avg)

1.01

Sales to Capital Employed (avg)

0.58

Tax Ratio

24.13%

Dividend Payout Ratio

62.91%

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

19.37%

ROE (avg)

25.39%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.79

EV to EBIT

19.40

EV to EBITDA

15.12

EV to Capital Employed

3.26

EV to Sales

5.21

PEG Ratio

2.92

Dividend Yield

20.45%

ROCE (Latest)

16.80%

ROE (Latest)

23.07%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 3 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 4.73% vs -1.80% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 6.44% vs 20.97% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "662.20",
          "val2": "632.30",
          "chgp": "4.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.00",
          "val2": "232.40",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "23.20",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-15.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "117.30",
          "val2": "110.20",
          "chgp": "6.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "286.60%",
          "chgp": "-28.66%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 11.82% vs 12.45% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 6.51% vs 7.01% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,618.40",
          "val2": "2,341.60",
          "chgp": "11.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.00",
          "val2": "826.90",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "81.20",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-22.40",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "443.60",
          "val2": "416.50",
          "chgp": "6.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "281.80%",
          "chgp": "-28.18%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

662.20

632.30

4.73%

Operating Profit (PBDIT) excl Other Income

0.00

232.40

-100.00%

Interest

0.00

23.20

-100.00%

Exceptional Items

0.00

-15.20

100.00%

Consolidate Net Profit

117.30

110.20

6.44%

Operating Profit Margin (Excl OI)

0.00%

286.60%

-28.66%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 4.73% vs -1.80% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 6.44% vs 20.97% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

2,618.40

2,341.60

11.82%

Operating Profit (PBDIT) excl Other Income

0.00

826.90

-100.00%

Interest

0.00

81.20

-100.00%

Exceptional Items

0.00

-22.40

100.00%

Consolidate Net Profit

443.60

416.50

6.51%

Operating Profit Margin (Excl OI)

0.00%

281.80%

-28.18%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 11.82% vs 12.45% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 6.51% vs 7.01% in Dec 2024

All Annual Results

Company CV

About Recordati SpA

Recordati SpA

Pharmaceuticals & Biotechnology

Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.

Company Coordinates

Company Details

Via M. Civitali, 1 , MILANO None : 20148

Tel: 39 02 48787139 02 48787393

https://www.recordati.com/

Registrar Details